A Phase 1 and Pharmacokinetic Study of Uproleselan (GMI-1271, NSC #801708) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome or Mixed Phenotype Acute Leukemia That Expresses E-selectin Ligand on the Cell Membrane and is in Second or Greater Relapse or That is Refractory to Relapse Therapy

This phase I trial tests the safety, side effects, and determination of the best dose of uproleselan in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia, myelodysplastic syndrome or mixed phenotype acute leukemia that has come back (relapsed) or does not respond to treatment (refractory) and that expresses E-selectin ligand on the cell membrane. Uproleselan binds to E-selectin expressed on endothelial cells of the bone marrow and prevents their interaction with selectin-E ligand-expressing cancer cells. This may prevent leukemia cells from being sequestered in the bone marrow niche and escaping the effect of chemotherapy. Chemotherapy drugs, such as fludarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving uproleselan in combination with fludarabine and cytarabine may expose more cancer cells to the effect of chemotherapy.

Start Date10 Oct 2023

Sponsor / Collaborator

National Cancer Institute

[+1]

NCT05569512

/ TerminatedPhase 1IIT

A Phase 1/2 Trial of Uproleselan Combined With High Dose Busulfan Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for Patients With Chemotherapy Resistant Acute Myeloid Leukemia

This research study is studying a new drug, uproleselan, to see if it is safe and effective in decreasing relapse after stem cell transplant and improving leukemia-free survival in pediatric patients with acute myeloid leukemia (AML).
The name of the study drugs involved in this study are:
* Uproleselan
* Busulfan
* Clofarabine
* Fludarabine
* Tacrolimus
* Methotrexate
* Mycophenolate Mofetil

Start Date06 Oct 2022

Sponsor / Collaborator

Dana-Farber Cancer Institute, Inc.

[+1]

NCT05054543

/ TerminatedPhase 3

A Phase 3 Randomized, Double-Blinded Bridging Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Chinese Patients With Relapsed/Refractory Acute Myeloid Leukemia

This bridging study will evaluate the efficacy of uproleselan, a specific E-selectin antagonist, in combination with chemotherapy to treat Chinese relapsed/refractory AML patients, compared to chemotherapy alone. The safety of uproleselan when given with chemotherapy will also be investigated in patients with relapsed/refractory AML

Start Date17 Nov 2021

Sponsor / Collaborator

Apollomics, Inc. (United States)

100 Clinical Results associated with Uproleselan

100 Translational Medicine associated with Uproleselan

100 Patents (Medical) associated with Uproleselan

Literatures (Medical) associated with Uproleselan

01 Nov 2025·Transplantation and Cellular Therapy

A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate E-Selectin Inhibition with Uproleselan to Reduce Gastrointestinal Toxicity During Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Article

Author: DiPersio, John F ; Stockerl-Goldstein, Keith ; Vij, Ravi ; Gao, Feng ; Uy, Geoffrey L ; Ryan, Meaghan ; Christen, Brandon ; Slade, Michael J ; Schroeder, Mark A ; Mayeski, Chris ; Crees, Zachary D

01 Jun 2024·British journal of haematology

Combining 5‐azacitidine with the E‐selectin antagonist uproleselan is an effective strategy to augment responses in myelodysplasia and acute myeloid leukaemia

Article

Author: Magnani, John L. ; Lincz, Lisa F. ; Enjeti, Anoop K. ; Bond, Danielle R. ; Smith, Theodore A. G. ; Fogler, William E.

Summary:

The interaction of acute myeloid leukaemic (AML) blasts with the bone marrow (BM) microenvironment is a major determinant governing disease progression and resistance to treatment. The constitutive expression of E‐selectin in the vascular compartment of BM, a key endothelial cell factor, directly mediates chemoresistance via E‐selectin ligand/receptors. Despite the success of hypomethylating agent (HMA)‐containing regimens to induce remissions in older AML patients, the development of primary or secondary resistance is common. We report that following treatment with 5‐azacitidine, promoter regions regulating the biosynthesis of the E‐selectin ligands, sialyl Lewis X, become further hypomethylated. The resultant upregulation of these gene products, in particular α(1,3)‐fucosyltransferase VII (FUT7) and α(2,3)‐sialyltransferase IV (ST3GAL4), likely causes functional E‐selectin binding. When combined with the E‐selectin antagonist uproleselan, the adhesion to E‐selectin is reversed and the survival of mice transplanted with AML cells is prolonged. Finally, we present clinical evidence showing that BM myeloid cells from higher risk MDS and AML patients have the potential to bind E‐selectin, and these cells are more abundant in 5‐azacitidine‐non‐responsive patients. The collective data provide a strong rationale to evaluate 5‐azacitidine in combination with the E‐selectin antagonist, uproleselan, in this patient population.

01 Oct 2022·Clinical Lymphoma Myeloma & Leukemia

CT-207 Protracted Diarrhea from High-Dose Melphalan in Autologous Hematopoietic Transplantation: Response to Short Course of Oral Budesonide

Article

Author: Kamble, Rammurti ; Oki, Shalewa ; Cox, James ; Scholoff, Audrey ; Jacob, Susan ; Obi, Gloria ; Zhang, Yuqi ; Gong, Zimu ; Carrum, George

Approximately, 40% of patients receiving high dose melphalan (HDM) develop grade III or IV diarrhea (CTCAE 5.0) that promptly improves upon neutrophilic engraftment. Persistence of grade III diarrhea beyond 72 hours post-engraftment, though uncommon results in significant morbidity and prolongs hospitalization. Enlighten by a histopathologic finding of crypt inflammation, we utilized a short course of oral budesonide in a patient resulting in rapid resolution of diarrhea. We herein document 3 such cases and discuss their role in reducing morbidity and duration of hospitalization. All patients (age 44, 63 and 65, 2 female) received melphalan 200 mg/m². Neutrophilic engraftment occurred on day +11 in 2 patients and day +12 in 1. Persistent grade III diarrhea 72 hours after neutrophil engraftment is defined as protracted diarrhea from melphalan. Infectious workup included stool examination for salmonella, shigella, rotavirus, cryptosporidium, and clostridium difficile we negative. Colonoscopy in one patient confirmed patchy crypt apoptosis and crypt abscess formation. Standard supportive care including antidiarrheals offered no improvement. Oral budesonide (BUD)was introduced at 5, 7- and 16-days post-engraftment (day + 17, +18 and +27 of ASCT). The dose of BUD comprised 6 mg/day in 2 while one patient received a 9 mg/day dose. Two patients had rapid resolution of diarrhea within 48 hours, while the third patient improved in 7 days. Total duration of BUD was 2, 2, and 26 days. Patients received a total cumulative dose of 12 mg, 15 mg, and 117 mg. Time to discharge from BUD initiation was 2, 2, and 7 days. A translational model of melphalan-induced gut toxicity reveals drug-host-microbe interaction that drives tissue injury and inflammation. Palifermin, a recombinant human keratinocyte growth factor is effective in reducing diarrhea of HDM. However, its cost is prohibitive. While newer melphalan preparations are available and prevention of melphalan-induced GI toxicity is being studied (Uproleselan), a short course of oral budesonide provided rapid resolution and facilitated patient discharge. Oral BUD results in rapid resolution of lower GI toxicity of HDM and potentially lowers the cost of hospitalization.

News (Medical) associated with Uproleselan

20 Nov 2024

·medcitynews.com

Startup Valora Unveils a Sweet Way to Stop Cancer and Autoimmune Disease, Plus $30M for R&D - MedCity News

Checkpoint inhibitors transformed cancer treatment, bringing to patients immunotherapies now widely used to treat a range of tumors. But there are different types of checkpoints that interact with the immune system, and the scope of this drug research is expanding. Valora Therapeutics focuses on sugar molecules found all over cells and a particular mechanism that regulates them. The preclinical startup emerged from stealth on Wednesday with $30 million to advance its research. One way that cells communicate with the immune system is through glycans, sugar molecules found on the surfaces of all cells. The presence of these molecules are a key way that the body distinguishes foreign cells from cells that belong to the body. Communication happens as glycans displayed on one cell are recognized by lectins, proteins on other cells that bind to glycans. But in some diseases, this communication is dysregulated. In cancer, that can mean tumors send signals that suppress the immune system. In autoimmune disease, the signaling can lead to excessive immune cell activity. San Diego-based Valora targets the glyco-immune checkpoint, a regulatory pathway in which glycans interact with lectins, said Miguel Garcia-Guzman, the startup’s co-founder and CEO. Valora’s drugs are engineered antibodies. The antibody component provides the targeting ability for the therapy, just like currently available therapeutic antibodies. But Valora brings additional functionality with a domain that directly binds to glycans, blocking their interaction with lectins. Valora calls these drugs antibody-lectin chimeras, or AbLecs. Consumer / Employer Health Executives on Digital Transformation in Healthcare Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare. By MedCity News “In the case of cancer, we try to reduce the glyco-immune checkpoint so the immune system becomes active again,” Garcia-Guzman said. “In the case of autoimmune disease, we do the contrary.” Valora’s science is based on the research of Carolyn Bertozzi, the Stanford University professor credited with inventing bioorthogonal chemistry, chemical reactions that happen in living systems without interfering with native biochemical processes. Applications of this chemistry include drug targeting, and Bertozzi’s work in this field was recognized with the 2022 Nobel Prize in Chemistry. Garcia-Guzman’s experience includes posts at Vertex Pharmaceuticals and Rakuten Medical, a cancer drug developer that he founded. He learned about AbLecs from a pre-print that was published in 2022, and he reached out to Bertozzi to discuss forming a company around the science. Valora was founded in 2023 with a license to Bertozzi’s Stanford research. Bertozzi is a scientific co-founder of the startup. The other scientific co-founder is Jessica Stark, an MIT professor of biological engineering and chemical engineering whose postdoctoral research in Bertozzi’s lab focused on identifying and targeting glycans that act as immune checkpoints for cancer. Garcia-Guzman said the importance of the glyco-immune checkpoint in cancer and autoimmune disease has gained recognition in the last decade. But there are many glycans, and it’s difficult to modulate the ones that are unknown. He added that he was drawn to the AbLec technology because this approach is both simple and powerful in the way that it addresses the pathological signaling that you want to modulate. Health IT Reducing Clinical and Staff Burnout with AI Automation As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers. By Dr. Michael Blackman, Chief Medical Officer at Greenway Health There are other companies pursuing glycobiology drug research. GlycoMimetics was developing small molecule drugs that block certain lectins. Lead program uproleselan, an experimental treatment for acute myeloid leukemia, hit a setback over the summer when the FDA said it needed another study. That program’s future is now uncertain as GlycoMimetics is serving as a vehicle for Crescent Biopharma to go public via a reverse merger. Meanwhile, Palleon Pharmaceuticals is another glycobiology company based on Bertozzi’s research. The Waltham, Massachusetts-based biotech is developing drugs that edit glycans as a way to treat cancers and autoimmune disease. Palleon recently reported Phase 1/2 data demonstrating proof of mechanism in cancer. Garcia-Guzman said Valora’s new funding will enable the startup to develop in phases. The first phase is platform exploration and optimization with a broad range of AbLec molecules that use different antibodies and lectins. This work will be applied to both cancer and autoimmune disease. The next phase will be prioritizing the mechanisms most promising for therapeutic development. After that, the company will work to toward the preclinical research that could support an investigational new drug application. Garcia-Guzman said Valora is not currently looking for partnerships with large pharmaceutical companies, but the broad potential applications of the company’s technology may lead to such alliances in the future. Valora’s $30 million seed round was co-led by Avalon BioVentures, Bregua Corporation, and TigerGene. Alexandria Ventures and Correlation Ventures also participated. The startup is based at Avalon’s accelerator in San Diego.

Immunotherapy

06 Nov 2024

·www.businesswire.com

GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

ROCKVILLE, Md.--( BUSINESS WIRE )--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML) have been accepted for presentation at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego, California, on December 7-10, 2024. ASH Annual Meeting abstracts may be accessed online at www.hematology.org . Details of GlycoMimetics presentations are as follows (all times PT): Publication Number: 733 Type: Oral Title: Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial Presenter: Daniel DeAngelo, M.D., Ph.D. Session Name: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: New Treatment Approaches for AML Session Date/ Presentation Time: Monday, December 9, 2024, 10:30 AM – 12:00 PM Publication Number: 1503 Type: Poster Title: Updated Results of a Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naive Acute Myeloid Leukemia Presenter: Brian Jonas, M.D., Ph.D. Session Name: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster I Session Date/ Presentation Time: Saturday, December 7, 2024, 5:30 PM - 7:30 PM Publication Number: 4262 Type: Poster Title: Final Results of a Phase II Study of Uproleselan Combined with Cladribine and Low-Dose Cytarabine for Patients with Treated Secondary Acute Myeloid Leukemia (ts-AML) Presenter: Caitlin Rausch, PharmD. Session Name: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III Session Date/Presentation Time: Monday, December 9, 2024, 6:00 – 8:00 PM About GlycoMimetics, Inc. GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The company’s scientific approach is based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform can be used to discover small molecule drugs, known as glycomimetics, that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. The company’s goal is to develop transformative therapies for diseases with high unmet medical need. GlycoMimetics is headquartered in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com . Forward-Looking Statements To the extent that statements contained herein are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of the management of GlycoMimetics, Inc. (“GlycoMimetics,” “we,” “us,” or “our”). Forward-looking statements include, but are not limited to, the expected presentation of clinical data for uproleselan, and any other statement containing terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “intends,” or “continue,” or the negative of these terms or other comparable terminology. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from those discussed, implied or otherwise anticipated by such statements. You are cautioned not to place undue reliance on such forward-looking statements, which are current only as of the date of this presentation. For a further description of the risks associated with forward-looking statements, as well as other risks facing GlycoMimetics, please see the risk factors described in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 27, 2024 and the Company’s Quarterly Reports on Form 10-Q filed with the SEC on May 9, 2024 and August 8, 2024, as well as other reports we file with the U.S. Securities and Exchange Commission from time to time, including those factors discussed under the caption “Risk Factors” in such filings. Forward-looking statements speak only as of the date of this presentation, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.

Phase 2Phase 1ASHClinical ResultPhase 3

29 Oct 2024

·medcitynews.com

Going In Reverse Is Faster Way Forward for Crescent Bio’s Cancer Immunotherapy - MedCity News

It’s hard for preclinical biotech companies to go public these days as investors look for human data that can reduce investment risk. Crescent Biopharma is more than a year away from the clinic, but joining the public markets now enables the biotech to capitalize on a recent groundbreaking cancer drug development still fresh in investors’ minds. Crescent is going public in a reverse merger with GlycoMimetics, the companies announced Tuesday. When the transaction is complete, the merged entity will operate under the Crescent Biopharma name. It will be led by Jonathan Violin, Crescent’s current CEO, who is expected to become interim CEO of the combined company. Crescent will also be capitalized with $200 million from agreements with a select group of investors that have pledged to purchase the combined company’s securities. Those purchases will happen immediately after the merger closes in the second quarter of 2025. Crescent’s lead program is CR-001, a bispecific antibody in development for cancer. Most companies trying to build an investment case talk about how their drugs are differentiated from rivals. Crescent’s executives are doing the opposite, touting similarities to another drug: Summit Therapeutics’ ivonescimab. Last month, that drug posted data showing it topped the blockbuster Merck immunotherapy Keytruda in a head-to-head Phase 3 test. In patients with advanced cases of non-small cell lung cancer, treatment with ivonescimab led to a 49% reduction in the risk of disease progression or death compared to treatment with Keytruda, Summit said. Sponsored Post The Funding Model for Cancer Innovation is Broken — We Can Fix It Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches. By Eve McDavid - CEO of Mission-Driven Tech Keytruda is an antibody designed to block a particular checkpoint protein, which in turn enables immune cells to recognize and go after cancer cells. Ivonescimab, discovered by Summit’s China-based partner Akeso, is a bispecific antibody that blocks two targets: PD-1, the same receptor targeted by Keytruda, and the cancer-driving protein VEGF. Crescent’s CR-001 is also a bispecific antibody designed to block both of those targets. Speaking during a Tuesday conference call, Violin said his company’s drug replicates the properties of ivonescimab. Like Summit’s drug, Crescent’s bispecific antibody works by cooperative binding, meaning it is most active in the presence of both VEGF and PD-1. “This enables the molecule to deliver benefits to patients that are more than the sum of its parts, and to do so safely,” Violin said. “This novel format enables VEGF to create ‘daisy chains’ of drug molecule, linking them together and increasing the potency for PD-1 blockade. This unique design also may enable localization of drug to the tumor microenvironment, which may help reduce systemic toxicity.” CR-001 is undergoing the preclinical research that could support an investigational new drug application, which is expected in the fourth quarter of next year or early 2026. Assuming the application is cleared, preliminary clinical data could come in the second half of 2026, Violin said. Because CR-001 replicates the properties of Summit’s drug, Crescent believes data from a few dozen patients can “connect the dots” back to data from hundreds of ivonescimab-treated patients. “We know the ivonescimab data has catalyzed massive interest in advancing next-generation checkpoint inhibitor therapy — the PD1/PDL1 class is currently a $50 billion market and growing, so when something beats the leader of such a large and important drug class, we expect competition,” Violin said. “We anticipate this will be similar to what we have seen recently in the obesity field — and we believe we have the advantage of strategic design. CR-001 was crafted specifically to thread the same immunotherapy needle as ivonescimab, putting us in a strong competitive position.” presented by Health IT Accelerating Claim Processing: Strategies to Shorten the Life of a Claim These strategies and practices can significantly shorten the life cycle of claims, leading to quicker resolutions and improved financial outcomes. By Greenway Health Competition includes BioNTech and Instil Bio, both of which struck alliances in the past year with China-based companies for rights to bispecific antibodies that target both PD-1 and VEGF. Both programs are in clinical development in China. Crescent is the fifth company to emerge from Paragon Therapeutics, a firm that conducts biotechnology research and forms new companies around that science. The first Paragon spinout was Apogee Therapeutics, which emerged in late 2022 with a lead drug candidate in development for atopic dermatitis. Last year, Apogee raised more than $300 million in a traditional IPO that came ahead of the start of Phase 1 testing. Crescent’s pipeline of drugs from Paragon includes two preclinical antibody drug conjugates, CR-002 and CR-003. The company isn’t disclosing much detail about either program, but Violin said CR-002 “targets a highly compelling pathway” and the drug offers “the chance to be first in class.” GlycoMimetics was focused on developing treatments for cancer and inflammatory diseases with small molecules that inhibit carbohydrate interactions on the surface of cells. In July, FDA told the company its lead drug candidate, uproleselan, a potential treatment for advanced cases of acute myeloid leukemia, needed an additional clinical trial. Subsequently, the company laid off staff announced it would explore strategic alternatives. Crescent said it intends to determine potential paths forward for uproleselan. The private investment in the newly merged Crescent will be led by Fairmount, Venrock Healthcare Capital Partners, BVF Partners, and an unnamed “large investment management firm.” Other participants include Paradigm BioCapital, RTW Investments, Blackstone Multi-Asset Investing, Frazier Life Sciences, Commodore Capital, Perceptive Advisers, Deep Track Capital, Boxer Capital Management, Soleus, Logos Capital, Driehaus Capital Management, Braidwell LP, and Wellington Management. When the business combination closes, Crescent’s stockholders will own about 96.9% of the company; GlycoMimetics stockholders will own about 3.1%. Crescent believes its capital will be sufficient to last into 2027. By then, Crescent and its peers should have more data demonstrating how their respective bispecific antibody cancer drugs are working in patients. Photo by Flickr user Lengyal Mark via a Creative Commons license

ImmunotherapyPhase 3IPOAcquisitionPhase 1

100 Deals associated with Uproleselan

External Link

KEGG	Wiki	ATC	Drug Bank
D11332	-	-	DB14829

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Relapsing acute myeloid leukemia	Phase 3	China	Apollomics, Inc. (United States)	17 Nov 2021
Adult Acute Myeloblastic Leukemia	Phase 3	China	Zhejiang Crownmab Biotech Co. Ltd.	27 Oct 2021
Adult Acute Myeloblastic Leukemia	Phase 3	China	Apollomics (Hong Kong) Limited	27 Oct 2021
Acute Promyelocytic Leukemia	Phase 3	United States	National Cancer Institute	28 Mar 2019
Refractory acute myeloid leukemia	Phase 3	United States	GlycoMimetics, Inc.	15 Oct 2018
Refractory acute myeloid leukemia	Phase 3	Australia	GlycoMimetics, Inc.	15 Oct 2018
Refractory acute myeloid leukemia	Phase 3	Canada	GlycoMimetics, Inc.	15 Oct 2018
Refractory acute myeloid leukemia	Phase 3	France	GlycoMimetics, Inc.	15 Oct 2018
Refractory acute myeloid leukemia	Phase 3	Ireland	GlycoMimetics, Inc.	15 Oct 2018
Refractory acute myeloid leukemia	Phase 3	Italy	GlycoMimetics, Inc.	15 Oct 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03701308 (Alliance A041701, CTgov)	Phase 2/3	Acute Myeloid Leukemia \| Acute Promyelocytic Leukemia	267	Multigated Acquisition Scan+Cytarabine+Daunorubicin (Arm I (Daunorubicin, Cytarabine))	hdfkgijduf(mwwfyeanky) = arwunprsjb ojuhqgseor (iafygzrytc, kpjccezkcb - zcyxrytbdg) View more	-	21 Jan 2026
				Multigated Acquisition Scan+Uproleselan+Cytarabine+Daunorubicin (Arm II (Uproleselan, Daunorubicin, Cytarabine))	hdfkgijduf(mwwfyeanky) = cwqvyfqbrf ojuhqgseor (iafygzrytc, edxrqnzzjn - ifbybfjari) View more
NCT03701308 (Alliance A041701, ASH2025)	Phase 2/3	Acute Myeloid Leukemia FLT3unmutated \| ASXL1 mutated	267	Uproleselan + conventional chemotherapy	iadkmkrhww(mfmufzhdub): HR = 0.71 (95.0% CI, 0.34 - 1.47), P-Value = 0.35 View more	Negative	06 Dec 2025
				Conventional chemotherapy
NCT04848974 (2922 \| Phase II Study of Uproleselan Combined with Cladribine and Low-Dose Cytarabine, CTgov)	Phase 1/2	Relapsing acute myeloid leukemia	37	Cladribine+Uproleselan+Cytarabine (Ph 1 Treatment Dose Level -1 Cladaribine 3.75mg/m^2)	lhguonwtob = ezcvdslaej pxbiiavivy (njsumhdrmy, zjpniljreg - qiprxkjqbk) View more	-	20 Oct 2025
				Cladribine+Uproleselan+Cytarabine (Ph 1 Treatment Dose Level 1 Cladaribine 5 mg/m^2)	lhguonwtob = pspwoiojdu pxbiiavivy (njsumhdrmy, ygikuogkar - sltjgzpjcn) View more
NCT05054543 (GlobeNewswire) Manual	Phase 3	Acute Myeloid Leukemia \| Refractory acute myeloid leukemia	140	Uproleselan with chemotherapyUproleselan with chemotherapy	mxzzyvsbor(dkvncaegzd) = oxunulbwwl cusyezceqr (xdmrsgjkwc, 6.1 - 16.0) Not Met View more	Negative	20 Dec 2024
				Chemotherapy alone	mxzzyvsbor(dkvncaegzd) = lhwzqujqpp cusyezceqr (xdmrsgjkwc, 6.2 - NA) Not Met View more
NCT04848974 (Phase II Study of Uproleselan Combined with Cladribine and Low-Dose Cytarabine, ASH2024)	Phase 2	Acute Myeloid Leukemia Consolidation	37	Uproleselan 800 mg IV	shjrwnqhdj(bcjzysmypc) = hychqndtbf jvlwkqvyyt (ztwsrqemzh ) View more	Positive	09 Dec 2024
NCT03701308 (NEWS)	Phase 2/3	Acute Myeloid Leukemia	-	Uproleselan	dsavldrbpb(filjtobtiu) = not reached the endpoint otdcyxlyvx (tqgcwembfv )	Negative	29 Oct 2024
NCT03616470 (Biospace) Manual	Phase 3	Acute Myeloid Leukemia	388	Uproleselan	gksmwhvlca(bxpghelrmk) = npbiazeeel oczkqrsnnv (roeqahfzfa ) View more	Positive	04 Jun 2024
				Placebo	gksmwhvlca(bxpghelrmk) = wtiyfgtqlj oczkqrsnnv (roeqahfzfa ) View more
NCT03616470 (Company_Website) Manual	Phase 3	Acute Myeloid Leukemia	388	Uproleselan	ulajrieyay(wmpqsajwnj) = idviehalkf iupotqajcc (omdpztxomd ) Not Met	Negative	06 May 2024
				placebo	ulajrieyay(wmpqsajwnj) = scuskzlwly iupotqajcc (omdpztxomd ) Not Met
NCT04682405 (CTgov)	Phase 2	Multiple Myeloma	51	Melphalan+Uproleselan (Uproleselan + Standard of Care Melphalan)	kfdxiedtnc(slbxsfsfrg) = oyyjtzunos hnnxjtwqef (mtackgtzif, 0.00) View more	-	15 Dec 2023
				Placebo+Melphalan (Placebo + Standard of Care Melphalan)	kfdxiedtnc(slbxsfsfrg) = krozuyrjgk hnnxjtwqef (mtackgtzif, 0.34) View more
NCT04848974 (ASH2023)	Phase 1/2	Acute Myeloid Leukemia	20	Uproleselan + Cladribine + LDAC	auufadqhqo(pcajcyitml) = ypvuobzcnp ramepyfuwp (bznwpjvdrz ) View more	-	10 Dec 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis